Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Kolette D. Fly"'
Autor:
David S. Hong, Ajay K. Gopal, Alexander N. Shoushtari, Sandip P. Patel, Aiwu R. He, Toshihiko Doi, Suresh S. Ramalingam, Amita Patnaik, Shahneen Sandhu, Ying Chen, Craig B. Davis, Timothy S. Fisher, Bo Huang, Kolette D. Fly, Antoni Ribas
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Section HeadClinical/translational cancer immunotherapyBackgroundThe goal of this study was to estimate the objective response rate for utomilumab in adults with immune checkpoint inhibitor (ICI)-refractory melanoma and non–small-cell lung cancer (
Externí odkaz:
https://doaj.org/article/a396b9eb0e0b40ccbf67fc789b9b7881
Autor:
Nancy L. Bartlett, Adrian Woolfson, Aron Thall, Kolette D. Fly, Bo Huang, Craig B. Davis, Ying Chen, Keith A. Ching, Shibing Deng, Xinmeng J. Mu, Caron Jacobson, Leslie Popplewell, Sandip P. Patel, Roch Houot, Ronald Levy, Ajay K. Gopal
Select laboratory abnormalities by maximum CTCAE grade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::773217ff965351d02fb30fb565157af9
https://doi.org/10.1158/1078-0432.22478279
https://doi.org/10.1158/1078-0432.22478279
Autor:
Nancy L. Bartlett, Adrian Woolfson, Aron Thall, Kolette D. Fly, Bo Huang, Craig B. Davis, Ying Chen, Keith A. Ching, Shibing Deng, Xinmeng J. Mu, Caron Jacobson, Leslie Popplewell, Sandip P. Patel, Roch Houot, Ronald Levy, Ajay K. Gopal
Gene signatures in baseline peripheral blood samples associated with prognosis in follicular lymphoma patients treated with rituximab and utomilumab. Higher, normalized enrichment scores (NES) correspond to poorer survival. NES were derived from gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0578952d771e83fd04fb0e64aa387d4d
https://doi.org/10.1158/1078-0432.22478285
https://doi.org/10.1158/1078-0432.22478285
Autor:
Craig Davis, Nancy L. Bartlett, Roch Houot, Aron Thall, Ronald Levy, Keith A. Ching, Leslie Popplewell, Sandip Pravin Patel, Adrian Woolfson, Bo Huang, Ying Chen, Xinmeng J. Mu, Ajay K. Gopal, Caron A. Jacobson, Kolette D. Fly, Shibing Deng
Publikováno v:
Clinical Cancer Research
Clinical Cancer Research, American Association for Cancer Research, 2020, 26 (11), pp.2524-2534. ⟨10.1158/1078-0432.CCR-19-2973⟩
Clinical Cancer Research, 2020, 26 (11), pp.2524-2534. ⟨10.1158/1078-0432.CCR-19-2973⟩
Clinical Cancer Research, American Association for Cancer Research, 2020, 26 (11), pp.2524-2534. ⟨10.1158/1078-0432.CCR-19-2973⟩
Clinical Cancer Research, 2020, 26 (11), pp.2524-2534. ⟨10.1158/1078-0432.CCR-19-2973⟩
Purpose: In this phase I study (NCT01307267), we evaluated safety, pharmacokinetics, clinical activity, and pharmacodynamics of treatment with utomilumab plus rituximab in patients with relapsed/refractory follicular lymphoma (FL) and other CD20+ non
Autor:
Ajay K, Gopal, Ronald, Levy, Roch, Houot, Sandip P, Patel, Leslie, Popplewell, Caron, Jacobson, Xinmeng J, Mu, Shibing, Deng, Keith A, Ching, Ying, Chen, Craig B, Davis, Bo, Huang, Kolette D, Fly, Aron, Thall, Adrian, Woolfson, Nancy L, Bartlett
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(11)
In this phase I study (NCT01307267), we evaluated safety, pharmacokinetics, clinical activity, and pharmacodynamics of treatment with utomilumab plus rituximab in patients with relapsed/refractory follicular lymphoma (FL) and other CD20Primary object
Autor:
H. Jean Khoury, Jean M. Aguiar, Carlo Gambacorti-Passerini, Svetoslav Dimitrov, Ewa Matczak, Jeffrey H. Lipton, Dmitri Pavlov, Mark Shapiro, Hagop M. Kantarjian, Jean-Bernard Durand, Kolette D. Fly, Jorge E. Cortes, Tim H. Brümmendorf, Michael J. Mauro, Eric Leip
Publikováno v:
American Journal of Hematology. 91:606-616
Vascular and cardiac safety during tyrosine kinase inhibitor (TKI) therapy is an emerging issue. We evaluated vascular/cardiac toxicities associated with long-term bosutinib treatment for Philadelphia chromosome-positive (Ph+) leukemia based on treat
Autor:
Jochen Schuette, Piotr Rutkowski, Peter Reichardt, Pamela E. Kaiser, Hans Gelderblom, Kolette D. Fly, Ewa Matczak, Elena Fumagalli, Liang Chen, Beatrice Seddon, Guido Biasco, Charles C. Williams, Lee S. Rosen, Herbert Hurwitz, Suayib Yalcin, Maria Jose Lechuga, George D. Demetri, Yoon-Koo Kang
Publikováno v:
Cancer. 121:1405-1413
BACKGROUND The objectives of this study were to provide sunitinib to patients with gastrointestinal stromal tumor (GIST) who were otherwise unable to obtain it and to collect broad safety and efficacy data from a large population of patients with adv
Autor:
Sudeep Gupta, Peter Reichardt, George D. Demetri, Jochen Schuette, Piotr Rutkowski, Seock-Ah Im, Jean-Yves Blay, Xin Huang, Michael Heinrich, Yoon-Koo Kang, Denis Soulières, Jean-Francois Martini, Kolette D. Fly, Patrick Schöffski, Maria Jose Lechuga, David Goldstein, Hans Gelderblom, Massimo Corsaro
Publikováno v:
BMC Cancer
BMC Cancer, BioMed Central, 2016, 16 (1), pp.22. ⟨10.1186/s12885-016-2051-5⟩
BMC Cancer, 16
BMC Cancer, BioMed Central, 2016, 16 (1), pp.22. ⟨10.1186/s12885-016-2051-5⟩
BMC Cancer, 16
Background Several small studies indicated that the genotype of KIT or platelet-derived growth factor receptor-α (PDGFRA) contributes in part to the level of clinical effectiveness of sunitinib in gastrointestinal stromal tumor (GIST) patients. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4af5b1f78a26398fd9ce5f51f6d846f2
https://hdl.handle.net/1887/112892
https://hdl.handle.net/1887/112892
Autor:
Jorge E, Cortes, H, Jean Khoury, Hagop, Kantarjian, Tim H, Brümmendorf, Michael J, Mauro, Ewa, Matczak, Dmitri, Pavlov, Jean M, Aguiar, Kolette D, Fly, Svetoslav, Dimitrov, Eric, Leip, Mark, Shapiro, Jeff H, Lipton, Jean-Bernard, Durand, Carlo, Gambacorti-Passerini
Vascular and cardiac safety during tyrosine kinase inhibitor (TKI) therapy is an emerging issue. We evaluated vascular/cardiac toxicities associated with long-term bosutinib treatment for Philadelphia chromosome-positive (Ph+) leukemia based on treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::03f4c65076df0273e71b73f7ddfaba62
http://hdl.handle.net/10281/115929
http://hdl.handle.net/10281/115929
Autor:
Jeffrey L. Vacirca, Graham P. Collins, Robert W. Chen, Gilles Salles, Armando Santoro, Stephen M. Ansell, Georg Hess, Douglas Laird, Martin Hutchings, Armando López-Guillermo, Adrian Woolfson, Wojciech Jurczak, Giovanna Andreola, Dmitri Pavlov, Daria Stypinski, Steven Le Gouill, Pier Luigi Zinzani, Kolette D. Fly, Fritz Offner
Publikováno v:
Journal of Clinical Oncology. 35:TPS7575-TPS7575
TPS7575 Background: Approximately 50% of patients (pts) with advanced DLBCL are refractory to or relapse following first line R-CHOP therapy. Pts with R/R DLBCL have limited treatment options and a poor prognosis. This study assesses immunotherapy-ba